Diarrhea intravenous

Trimethoprim-sulfamethoxazole (TMP-SMX) (20 mg/kg/day of trimethoprim) is the treatment of choice for P. carinii pneumonia (PCP). Oral therapy with TMP-SMX is reserved for children with mild PCP who do not have malabsorption or diarrhea. Intravenous pentamidine (4 mg/kg/day, given once a day) can be given to children with PCP who are intolerant of TMP-SMX or who have not responded after 5 days of TMP-SMX therapy. Other treatment regimens that may be considered for patients who are intolerant of or fail TMP-SMX and pentimidine are (1) atovaquone (40 mg/kg/ day, in two divided doses) for mild/moderate PCP only (2) dapsone with trimethoprim (3) trimetrexate with leucovorin and (4) clindamycin and primaquine. These alternate treatments have limited experience in pediatric patients. 

Irinotecan (CPT-11) is approved for colorectal tumors. It is given by intravenous infusion. The most severe side effect is diarrhea, which can be severe and needs to be treated by a physician. Temporary liver dysfunction is generally asymptomatic. The other side effects are the same as those produced by topotecan. 

The most common adverse reactions seen with this drug are related to the gastrointestinal tract and may include nausea, anorexia, and occasionally vomiting and diarrhea The most serious adverse reactions are associated widi die CNS and include seizures and numbness of die extremities. Hypersensitivity reactions also may be seen. Thrombophlebitis may occur widi intravenous (IV) use of die drug. 

Iron salts occasionally cause gastrointestinal irritation, nausea, vomiting, constipation, diarrhea, headache, backache, and allergic reactions. The stools usually appear darker (black). Iron dextran is given by the parenteral route Hypersensitivity reactions, including fatal anaphylactic reactions, have been reported with the use of this form of iron. Additional adverse reactions include soreness, inflammation, and sterile abscesses at the intramuscular (IM) injection site Intravenous (IV) administration may result in phlebitis at the injection site When iron is administered via the IM route, a brownish discoloration of tlie skin may occur. Fhtients with rheumatoid arthritis may experience an acute exacerbation of joint pain, and swelling may occur when iron dextran is administered. 

MANAGING DIARRHEA. Measures to manage diarrhea include a low-residue diet while the bowel rests. Electrolytes are monitored and supplemented as needed. Adequate hydration must be maintained intravenous fluids may be necessary. If diarrhea is severe, therapy may be delayed or stopped or the dose decreased. 

Alkyl olefinsulfonates (AOS) are essentially nontoxic with reported LD50 values in mice of 3000 mg/kg (oral), 1660 mg/kg (subcutaneous), 170 mg/kg (intraperitoneal), and 90 mg/kg (intravenous). The toxic signs seen at the higher doses included reduced voluntary activity, diarrhea, anemia, dyspnea, and respiratory collapse. Clonic convulsion followed by respiratory collapse was seen in mice given the material intravenously [147,148]. 

When sorbitol is administered intravenously, it is converted to fructose rather than to glucose. It is poorly absorbed in the small intestine, and much is fermented by colonic bacteria to short-chain fatty acids, CO2, and Hj, leading to abdominal pain and diarrhea (sorbitol intolerance). 

In addition to these two applications, intravenous nutrition and fluid therapy has been given for many years to newborns with chronic diarrhea, malabsorption for various reasons, and other problems associated with disease. 

Most common Sedation, restlessness, diarrhea (metoclopramide), agitation, central nervous system depression Less common Extrapyramidal effects (more frequent with higher doses), hypotension, neuroleptic syndrome, supraventricular tachycardia (with intravenous administration)... 

N, nausea D, diarrhea HA, headache SOB, shortness of breath HTN, hypertension LFTs, liver function tests CBC, complete blood count ISR, injection-site reactions IR, infusion reactions IV, intravenous MYL, myelosuppression (watch for fever, symptoms of infection, easy bruisability, and bleeding) SC, subcutaneous. 

Topotecan inhibits topoisomerase I to cause single-strand breaks in DNA. The pharmacokinetics of topotecan can be described by a two-compartment model, with a terminal half-life of 80 to 180 minutes, with renal clearance accounting for approximately 70% of the clearance.19 Topotecan has shown clinical activity in the treatment of ovarian and lung cancer, myelodysplastic syndromes, and acute myelogenous leukemia. The intravenous infusion may be daily for 5 days or once weekly. Side effects include myelosuppression, mucositis, and diarrhea. 

Diarrhea may occur from effects of chemotherapy on the lower portion of the GI tract. Diarrhea can be severe and may need to be treated with intravenous fluids and electrolytes. Infectious causes, such as C. difficile, should be ruled out. Pharmacologic therapy of diarrhea can range from loperamide or cholestyramine to octreotide for severe cases of diarrhea that are refractory to usual treatments. 

Clearly, the route of administration of antibiotics can affect the rates of AAD. Rates of diarrhea are lower with intravenous than oral antibiotics. Specific rates of diarrhea for all individual antibiotics are not available. Some... 

A 75- year-old woman is hospitalized for pneumonia and treated with an intravenous antibiotic. On day threet she develops severe diarrhea. Stool is positive for Clostridium difficile toxin What is the best treatment ... 

IMMUNODEFICIENCY WITH HYPER-IGM (HIGMl), AN IMMUNOGLOBULIN ISOTYPE SWITCH DEFECT CHARACTERIZED BY ELEVATED CONCENTRATIONS OF SERUM IGM AND DECREASED AMOUNTS OF ALL OTHER ISOTYPES. AFFECTED MALES PRESENT AT AN EARLY AGE (USUALLY WITHIN THE FIRST YEAR OF LIFE) RECURRENT BACTERIAL AND OPPORTUNISTIC INFECTIONS, INCLUDING PNEUMOCYSTIS CARINII PNEUMONIA AND INTRACTABLE DIARRHEA DUE TO CRYPTOSPORIDIUM INFECTION. DESPITE SUBSTITUTION TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN, THE OVERALL PROGNOSIS IS RATHER POOR, WITH A DEATH RATE OF ABOUT 10% BEFORE ADOLESCENCE. 

Incidents of vincristine overdosage have been reported relatively frequently in the medical literature. Some of these have involved inadvertent administration of the intravenous formulation into the central nervous system by the intrathecal route this produces devastating results by a combination of chemical damage to sensitive neuronal tissue as well as biochemical perturbations. Two representative cases of vincristine overdose were described (46) involving administration of vincristine to patients scheduled to receive vinblastine. In one patient toxicity initially involved vomiting and diarrhea with subsequent constipation and paralytic ileus (inhibition of motor activity in the small intestine). Muscle pain... 

SYMPTOMS - After several hours (ingested) -diarrhea, abdominal pain, nausea, and vomiting. Cause of death is respiratory paralysis. Intravenous dose works much quicker, causing sudden death without any symptoms. 

Azathioprine can be administered both orally and intravenously. It is well absorbed orally and after its rapid conversion to 6-mercaptopurine it is inactivated by xanthine oxidase which converts 6-mercaptopurine to 6-thiouric acid. This final metabolite is then excreted in the urine. In combination with the xanthine oxidase inhibitor allopurinol dose adjustments of azathioprine are needed. Renal disease also raises 6-mercaptopurine concentrations and can make dose adjustments necessary. Azathioprine is still used in organ transplantation programs and for the management of several autoimmune diseases. Its adverse effects include nausea, vomiting, diarrhea and, more seriously, bone marrow suppression and hepatotoxicity. Azathioprine is not thought to cause fetal malformation. 

---